Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common breast cancer drug and a supplement boost sperm quality?

NCT ID NCT07669402

Disease control Sponsor: Tehran University of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This study tested whether letrozole (a drug that lowers estrogen) and L-carnitine (a natural supplement) could improve sperm quality in 90 men with unexplained infertility. Participants took one of the treatments or a combination for three months. The goal was to see changes in sperm count, movement, and shape, as well as markers of oxidative stress. Results could lead to new, non-invasive fertility treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Letrozole and L-carnitine
What this could lead to
If successful, this could point toward a simple, drug-based way to improve sperm quality and fertility outcomes in men with unexplained infertility.
What could go wrong
This is a small, early-phase trial (90 men) with short treatment duration. Results may not apply to all men, and benefits may be modest or not lead to higher pregnancy rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

90 people

The number who actually took part.

Started

Dec 2023

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 45 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Diagnosis of idiopathic oligoasthenoteratozoospermia (iOAT) per WHO 2021 criteria Age 20 to 45 years BMI between 18 and 30 kg/m² No prior hormonal therapy or antioxidant supplements within the last 3 months Exclusion Criteria: Varicocele, cryptorchidism, or genital tract infection Hormonal disorders (hypogonadism, hyperprolactinemia, thyroid dysfunction) Smoking, alcohol use, or drug abuse Use of testosterone or anabolic steroids within the last 6 months Female partner with severe infertility factors (age ≥40, tubal blockage, severe endometriosis)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic oligoasthenoteratozoospermia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

male infertility oligoasthenoteratozoospermia oligospermia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Idiopathic oligoasthenoteratozoospermia Male infertility

Contacts and locations

Locations

  • Shariati Hospital, Tehran University of Medical Sciences

    Tehran, 1417613151, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.